Investor Presentaiton slide image

Investor Presentaiton

iber/mezi Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab GPRC5D Phase 3 INDEPENDENCE 1L TD anemia in MF trial design1 Key Eligibility Criteria: MPN-associated MF • Stable dose JAK2 inhibitor • Transfusion dependent Stratification: Blinded Core Treatment Period (24 weeks) Extended Treatment (Week 25+) Luspatercept + JAK2i SQ every 3 weeks • BL RBC transfusion burden R DIPSS (intermediate vs. high) 2:1 Primary Endpoint: • RBC transfusion independence Placebo + JAK2i SQ every 3 weeks Day 169 Response Assessment: RBC-TI 12W/24W Continued Treatment Crossover from placebo to lusptercept allowed if no response at primary endpoint response assessment for ≥12 weeks Key Secondary Endpoint: RBC transfusion independence for ≥16 weeks Ill Bristol Myers Squibb™ 1. NCT04717414 Expected data readout 2025 Not for Product Promotional Use 76
View entire presentation